Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
Opponents of marijuana rescheduling are using a coordinated legal playbook to push court briefings into…
Six years after his last album, the artist who still can’t understand why anyone calls…
Puerto Rico’s new Act 204-2026 creates an exception to workplace protections for registered medical cannabis…
A new survey conducted in September among 1,008 U.S. adults interested in hiking and camping…
“I didn’t invent it. I described it.” Five days, no budget and 26 rounds of…
Legalization was sold as a finish line. Regulators in four states say it was the…